FdaApplication
ANDA 212219
Identifiers
- fda_app_no: ANDA212219
Properties
| Property | Value |
|---|---|
| applicant_name | BAXTER HEALTHCARE CORP |
| application_type | ANDA |
| approval_date | 2022-10-19 |
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | DOXORUBICIN HYDROCHLORIDE | 50MG/25ML (2MG/ML) | INJECTABLE, LIPOSOMAL;INJECTION |
| DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | DOXORUBICIN HYDROCHLORIDE | 20MG/10ML (2MG/ML) | INJECTABLE, LIPOSOMAL;INJECTION |
2 products